- Home
- NMIH vs FOLD Comparison
NMIH vs FOLD Comparison
Compare NMIH & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMIH
- FOLD
- Stock Information
- Founded
- NMIH 2011
- FOLD 2002
- Country
- NMIH United States
- FOLD United States
- Employees
- NMIH N/A
- FOLD N/A
- Industry
- NMIH Property-Casualty Insurers
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- NMIH Finance
- FOLD Health Care
- Exchange
- NMIH Nasdaq
- FOLD Nasdaq
- Market Cap
- NMIH 3.2B
- FOLD 2.9B
- IPO Year
- NMIH 2013
- FOLD 2007
- Fundamental
- Price
- NMIH $37.81
- FOLD $6.12
- Analyst Decision
- NMIH Buy
- FOLD Buy
- Analyst Count
- NMIH 7
- FOLD 10
- Target Price
- NMIH $43.00
- FOLD $16.22
- AVG Volume (30 Days)
- NMIH 535.0K
- FOLD 5.5M
- Earning Date
- NMIH 07-29-2025
- FOLD 08-07-2025
- Dividend Yield
- NMIH N/A
- FOLD N/A
- EPS Growth
- NMIH 14.57
- FOLD N/A
- EPS
- NMIH 4.63
- FOLD N/A
- Revenue
- NMIH $667,964,000.00
- FOLD $543,141,000.00
- Revenue This Year
- NMIH N/A
- FOLD $19.84
- Revenue Next Year
- NMIH $3.93
- FOLD $23.18
- P/E Ratio
- NMIH $8.34
- FOLD N/A
- Revenue Growth
- NMIH 11.61
- FOLD 28.25
- 52 Week Low
- NMIH $31.90
- FOLD $5.51
- 52 Week High
- NMIH $43.20
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- NMIH 34.40
- FOLD 51.42
- Support Level
- NMIH $41.77
- FOLD $5.66
- Resistance Level
- NMIH $43.20
- FOLD $6.45
- Average True Range (ATR)
- NMIH 0.89
- FOLD 0.21
- MACD
- NMIH -0.58
- FOLD 0.07
- Stochastic Oscillator
- NMIH 0.92
- FOLD 64.89
About NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.